Nektar Therapeutics
NKTR
133 hedge funds and large institutions have $168M invested in Nektar Therapeutics in 2024 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 36 increasing their positions, 34 reducing their positions, and 24 closing their positions.
59% more capital invested
Capital invested by funds: $106M → $168M (+$62.4M)
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
7% more funds holding
Funds holding: 124 → 133 (+9)
6% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 34
0.8% more ownership
Funds ownership: 4.1% → 4.91% (+0.8%)
35% less call options, than puts
Call options by funds: $50K | Put options by funds: $77K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$13.3M |
| 2 |
BlackRock
New York
|
+$13M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$10.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.28M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
Monaco Asset Management
Monaco
|
-$5.15M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.77M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.25M |
| 4 |
D.E. Shaw & Co
New York
|
-$3.09M |
| 5 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$1.93M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FCBT
151
First Citizens Bank & Trust
Raleigh,
North Carolina
| – | -$10.9K | -779 | Closed |
|
|
GS
152
GTS Securities
New York
| – | -$10.6K | -759 | Closed |
|
153
First Manhattan
New York
| – | -$467 | -33 | Closed |
|
|
AWM
154
Avior Wealth Management
Omaha,
Nebraska
| – | -$186 | -13 | Closed |
|
|
CSS
155
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$37 | -3 | Closed |
|
|
C
156
Covestor
London,
United Kingdom
| – | -$42 | -2 | Closed |
|
157
AssetMark Inc
Concord,
California
| – | -$21 | -1 | Closed |
|
NKTR Hedge Fund Activity: Q2 2024 in Review
133 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2024, worth a combined $168M — up 59% from $106M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new NKTR positions and 24 closed out — a net gain of 12 holders — while 36 added to existing stakes and 34 trimmed.
The largest buyer was Samlyn Capital, opening a new position worth an estimated $13.3M. The largest seller was Monaco Asset Management, cutting an estimated $5.15M.
- 133 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2024, up from 124 in Q1 2024.
- Funds reported $168M of Nektar Therapeutics stock for Q2 2024, up 59% quarter-over-quarter.
- 36 funds opened new Nektar Therapeutics positions in Q2 2024 and 24 closed out, a net change of +12 holders.
- The largest Nektar Therapeutics buyer in Q2 2024 was Samlyn Capital, an estimated $13.3M added.
- The largest Nektar Therapeutics seller in Q2 2024 was Monaco Asset Management, an estimated $5.15M sold.
Based on aggregated 13F filings for Q2 2024.